LivaNova PLC
LIVN
Classifica tra le azioni
#3783
LivaNova PLC is a global medical technology company dedicated to developing,... LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Prezzo delle azioni
$80.35
Ultima sincronizzazione: 2026-10-20
Capitalizzazione di mercato
$4.41B
Variazione (1 giorno)
2.83%
Variazione (1 anno)
46.87%
Paese
GB
Scambia LivaNova PLC (LIVN)
Categoria
Healthcare
Rapporto P/B per LivaNova PLC (LIVN)
Rapporto P/B al October 2026 TTM: 3.16
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di LivaNova PLC, il rapporto P/B attuale (TTM) è 3.16. Alla fine del 2023, era pari a 2.18.
Storico del rapporto P/B per LivaNova PLC da 2000 a 2026
Rapporto P/B alla fine di ogni anno
| Anno | Rapporto P/B | Cambia |
|---|---|---|
| 2026 (TTM) | 3.16 | 66.17% |
| 2024 | 1.90 | -12.84% |
| 2023 | 2.18 | -11.24% |
| 2022 | 2.46 | -28.08% |
| 2021 | 3.42 | 18.91% |
| 2020 | 2.88 | 9.10% |
| 2019 | 2.64 | -10.65% |
| 2018 | 2.95 | 39.02% |
| 2017 | 2.12 | 64.84% |
| 2016 | 1.29 | 48.82% |
| 2015 | 0.87 | -89.71% |
| 2013 | 8.41 | -20.72% |
| 2012 | 10.61 | -5.13% |
| 2011 | 11.18 | -36.02% |
| 2010 | 17.47 | -77.09% |
| 2009 | 76.29 | -162.67% |
| 2008 | -121.73 | 9.58% |
| 2007 | -111.08 | -129.52% |
| 2006 | 376.35 | 1,592.58% |
| 2005 | 22.24 | -5.01% |
| 2004 | 23.41 | -26.31% |
| 2003 | 31.76 | -23.20% |
| 2002 | 41.36 | 0.00% |
| 2001 | 0.00 | -100.00% |
| 2000 | 32.85 | 0.00% |
Rapporto P/B per aziende simili o concorrenti
| Azienda | Rapporto P/B | Differenza del rapporto P/B | Il paese |
|---|---|---|---|
| 3.5116 | 11.22% |
US
|
|
| 2.0146 | -36.19% |
IE
|
|
| 4.5025 | 42.61% |
US
|
|
| 2.5486 | -19.28% |
US
|
|
| - | - |
DE
|
